A Phase 2 trial of intravenous CBD Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2018
Price : $35 *
At a glance
- Drugs Cannabidiol (Primary)
- Indications Cerebral ischaemia
- Focus Therapeutic Use
- 27 Nov 2018 According to a GW Pharmaceuticals media release, the company expects to start this study in H1 2019.
- 27 Nov 2018 Planned initiation date changed to 1 Jan 2019, according to a GW Pharmaceuticals media release.
- 17 Aug 2018 New trial record